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June 2016 noted. In a substudy, baseline and 24±3-hour computed tomographic brain scans were performed and analyzed centrally. ANCOVA models assessed associations of SBP reduction on 24-hour hematoma growth.
Results
Among 2839 participants of the INTERACT2 study, 964 (40%) were included in the computed tomographic substudy. Compared with patients without a follow-up computed tomography, they were more often on anticoagulation or antiplatelet therapy, had higher National Institute of Health Stroke Scale scores, and shorter time from symptoms onset to randomization at baseline ( Table I in the online-only Data Supplement). However, the 2 groups were similar with regard to baseline SBP, ICH volume and location, and allocation to intensive BP-lowering treatment. Table II in the online-only Data Supplement shows the patient characteristics by the degree of SBP reduction: those with the smallest ΔSBP (<10 mm Hg) were older and those with greatest ΔSBP (≥20 mm Hg) were more often women, with a history of ICH, higher baseline BP, and more often included to intensive BP-lowering group (420 [59%] ; P<0.001). A greater degree of SBP reduction was associated with less hematoma growth: ∆SBP 1-24 h at <10-, 10-to 20-, and ≥20-mm Hg reduction was associated with hematoma growth (mL) of 13.3 (9.0-17.5), 5.0 (1.6-8.4), and 3.0 (0.5-5.4) , respectively (P trend<0.001). A similar trend was observed for the same degrees of ∆SBP 15-60 mol/L , but this was not statistically significant ( Figure 1 ). There was no significant difference in the relation of SBP reduction and hematoma growth in patients with baseline SBP levels above or below 180 mm Hg for any of ∆SBP 1-24 h or ∆SBP 15-60 mol/L (P homogeneity=0.133 and 0.999, respectively; Table III in the online-only Data Supplement). The results were similar in a sensitivity analysis stratified for trial treatment without any heterogeneity (Table IV in the online-only Data Supplement) . Table V in the online-only Data Supplement shows the participants' baseline characteristics, which are grouped by time from symptom onset to randomization and were broadly similar between groups, except more patients allocated intensive treatment were on anticoagulation in at 3 to 4.5 hours. There was no association of intensive treatment with hematoma growth in these subgroups by time to treatment in crude or adjusted models (P trend=0.691 and 0.702, respectively; Figure 2 ; Table VI in the online-only Data Supplement).
Of 491 patients randomized to intensive BP lowering, the SBP target was achieved in 242 (49%) and 125 (25%) <1 and 1 to 6 hours, respectively; 124 (25%) did not achieve target <6 hours. The least hematoma growth (mL) was in those achieving target SBP early (≤1 hour; 2.6; 95% confidence interval, 0.1-5.2) compared with later periods 1 to 6 hour (4.7; 95% confidence interval, 1.8-7.5) and >6 hours (5.4; 95% confidence interval, 2.4-8.3 ; P trend=0.029; Figure 3A ).
Hematoma growth was 5.2 (95% confidence interval, 2.7-1.8), 3.1 (0.3-6 .0), and 0.4 (-1.1 to 5.1), respectively, according to 0 to 2, 3 to 4, and 5 to 8 times to target SBP (P trend=0.018; Figure 3B ).
Discussion
These analyses of INTERACT2 show that a greater fall in SBP was associated with less hematoma growth, irrespective of whether patients received intensive or guideline-based BP-lowering treatment. Patients with the least hematoma growth were those who achieved target SBP of <140 mm Hg within the first hour and in those who sustained this target throughout the first 24 hours. These data are relevant for patient management, where early, intensive, and consistent lowering of SBP seems to offer the greatest potential to improve outcome in ICH, including better functional recovery in those with smooth BP control. 4 These results also support recent guideline recommendations for more intensive BP management in ICH.
Outcome in ICH depends on the size and growth of the underlying hematoma, 5, 6 which are related to mechanisms of intravascular hydrostatic pressure, local tissue pressure, and mechanical injury to brain tissue and blood vessels, cerebral blood flow, plasma protein induction, and inflammation. 7, 8 Other important factors that may influence hematoma growth include timing of imaging and baseline hematoma volume. Greater SBP reduction and shorter time to target SBP being associated with the least hematoma growth could be related to intensive BP lowering producing larger and faster decreases in intravascular hydrostatic pressure secondary arteriolar rupture. This analyses could not confirm the other mechanisms stated above. Our earlier analyses have shown a linear relationship between achieved SBP and disability in both the hyperacute (1-24 hours) and acute (2-7 days) phases, 9 and similar findings have been reported in other populations. 10, 11 Although our study included a large and heterogeneous population with rigorous prospective and systematic evaluations of both BP and hematoma growth, the analyses are limited by selection bias, inability to establish a causal relationship with treatment, and in being post hoc and not prespecified.
In conclusion, these analyses suggest potential beneficial effects of early and controlled BP-lowering treatment through attenuation of hematoma growth. 
Supplemental

Medical History
Prior ICH 3 (3) 17 (11) 38 (5) 0.008
Prior ischemic stroke 11 (11) 14 (9) 59 (8) 0.598
Prior acute coronary event 6 (6) 7 (5) 23 (3) 0.296
Diabetes mellitus 14 (14) 22 (15) 94 (13) 0.863
History of hypertension 69 (70) 111 (74) 507 (71) 0.742
Use of antihypertensive therapy 55 (56) 79 (53) 351 (51) 0.596
Use of warfarin anticoagulation 3 (3) 13 (9) 35 (5) Data are n (%), mean (SD), or median (IQR). P values are based on chi-squared or Wilcoxon test. BP indicates blood pressure; GCS, Glasgow coma scale; ICH, intracerebral hemorrhage; NIHSS, National Institutes of Health stroke scale; CT, computed tomography. *NIHSS scores range from 0 (normal, no neurological deficit) to 42 (coma with quadriplegia). †basal ganglia or thalamus.
Supplemental Table III . The effect of systolic blood pressure (SBP) reduction (baseline -average in the 1 to 24 hour period) on hematoma growth stratified by baseline SBP* Baseline SBP, mmHg BP reduction degree, mean (95%CI) P trend P homogeneity <10
10-20 ≥20 Baseline -average (1-24 hours) (mL) <180 (N=496) 12.5 (7.4-17.6) 2.8 (-1.4-7.0) 3.1 (-0.6-6.8) 0.001 0.133 ≥180 (N=467) 8.3 (-3.3-19.9) 
